Positive News SentimentPositive NewsNASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis $2.03 +0.07 (+3.52%) As of 12:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OmniAb Stock (NASDAQ:OABI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OmniAb alerts:Sign Up Key Stats Today's Range$1.92▼$2.0250-Day Range$1.25▼$2.2052-Week Range$1.22▼$4.95Volume137,794 shsAverage Volume797,115 shsMarket Capitalization$247.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. Read More OmniAb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreOABI MarketRank™: OmniAb scored higher than 60% of companies evaluated by MarketBeat, and ranked 445th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmniAb has only been the subject of 1 research reports in the past 90 days.Read more about OmniAb's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OmniAb's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.16% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in OmniAb has recently increased by 3.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.16% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in OmniAb has recently increased by 3.86%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment1.71 News SentimentOmniAb has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OmniAb this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought more of their company's stock than they have sold. Specifically, they have bought $130,100.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OmniAb's insider trading history. Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Stock News HeadlinesOmniAb to Report Second Quarter 2025 Financial Results on August 6July 16, 2025 | businesswire.comPositive week for OmniAb, Inc. (NASDAQ:OABI) institutional investors who lost 47% over the past yearJuly 4, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.July 30 at 2:00 AM | Porter & Company (Ad)Chairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSee More Headlines OABI Stock Analysis - Frequently Asked Questions How have OABI shares performed this year? OmniAb's stock was trading at $3.54 on January 1st, 2025. Since then, OABI stock has decreased by 43.4% and is now trading at $2.0050. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). The company earned $4.15 million during the quarter, compared to the consensus estimate of $4.49 million. OmniAb had a negative net margin of 229.11% and a negative trailing twelve-month return on equity of 21.37%. Read the conference call transcript. Who are OmniAb's major shareholders? OmniAb's top institutional investors include Woodstock Corp (0.51%), Public Employees Retirement System of Ohio (0.08%) and Vanguard Personalized Indexing Management LLC (0.04%). Insiders that own company stock include Matthew W Foehr, John L Higgins, Charles S Berkman, Kurt A Gustafson, Jennifer R Cochran and Steven Love. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OmniAb own? Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings5/08/2025Today7/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBusiness Services Current SymbolNASDAQ:OABI CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for OmniAb$7.00 High Price Target$11.00 Low Price Target$4.00 Potential Upside/Downside+257.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.03 million Net Margins-229.11% Pretax Margin-254.78% Return on Equity-21.37% Return on Assets-18.84% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.70 Sales & Book Value Annual Sales$26.74 million Price / Sales8.95 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.83Miscellaneous Outstanding Shares122,135,000Free Float111,631,000Market Cap$239.38 million OptionableOptionable Beta0.14 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:OABI) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OmniAb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.